bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1 - 10, Tables 1 - 11 from Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Molina-Vila Miguel A. , Bertran-Alamillo Jordi , Gascó Amaya , Mayo-de-las-Casas Clara , Sánchez-Ronco María , Pujantell-Pastor Laia , Bonanno Laura , Favaretto Adolfo G. , Cardona Andrés F. , Vergnenègre Alain , Majem Margarita , Massuti Bartomeu , Morán Teresa , Carcereny Enric , Viteri Santiago , Rosell Rafael
Published: April 2023

PDF file - 280KB, Supplementary Table S1. Primers for TP53 genotyping. Supplementary Table S2. Cell lines used as controls for TP53, KRAS, BRAF and PIK3CA genotyping. Supplementary Table S3. Amplification conditions for TP53 genotyping. Supplementary Table S4. Primers for k-RAS, BRAF and PIK3CA genotyping. Supplementary Table S5. Amplification conditions for KRAS, BRAF and PIK3CA genotyping. Supplementary Table S6: Additional clinical and biological characteristics of the patients in the training and validation cohorts, according to EGFR status. Supplementary Table S7: Characteristics of the patients in the training cohort, classified according to EGFR and TP53 status. Supplementary Table S8: List of observed TP53 mutations (training and validation cohorts). Supplementary Table S9: Univariate Cox regression analysis of selected factors for overall survival in the EGFR-wt and EGFR-mut populations of the training cohort. Supplementary Table S10: Results of multivariate analysis of selected factors for overall survival in the EGFR-wt and EGFR-mut groups of the training cohort. Supplementary Table S11: GOF activities in cell line models of some nondisruptive TP53 mutations found in this study. Supplementary Figure S1: Structure of the TP53 protein representing the location of the mutations found in the training cohort. Supplementary Figure S2: Types of TP53 mutations in the training and validation cohorts. Supplementary Figure S3: Distribution of KRAS, BRAF and PIK3CA mutations in the training cohort. Supplementary Figure S4. Kaplan-Meier plots of overall and progression-free survival of the 318 patients in the training cohort, according to EGFR mutational status. Supplementary Figure S5. Kaplan-Meier plots of overall survival of the 125 EGFR-wt patients in the training cohort, according to G12C mutations in K-RAS. Supplementary Figure S6: Kaplan-Meier plots of overall and progression-free survival of the 318 patients in the training cohort, according to TP53 status. Supplementary Figure S7. Kaplan-Meier plots of overall survival of the 110 EGFR-wt patients in the training cohort not carrying G12C mutations in K-RAS. Supplementary Figure S8: Kaplan-Meier plots of progression-free survival of the 318 patients in the training cohort, according to TP53 mutational status. Supplementary Figure S9: Kaplan-Meier plots of progression-free survival in the training cohort, according to EGFR and TP53 mutational status. Supplementary Figure S10: Kaplan-Meier plots of progression-free survival in the training cohort, according to type of treatment.
Supplementary Figure 3 from L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
Authors: Mehta Neelima R. , Wurz Gregory T. , Burich Rebekah A. , Greenberg Brittany E. , Griffey Stephen , Gutierrez Audrey , Bell Katie E. , McCall Jamie L. , Wolf Michael , DeGregorio Michael
Published: April 2023

PDF file - 119K, Percentage cytotoxicity was measured in hMUC1 expressing breast cancer target cells (derived from an MMT tumor) after 60 min incubation with CD8 effectors derived from vaccinated/placebo or untreated mice. (A) CD8+ effector cells from mice were purified and incubated at a 5:1 effector to target ratio (N=1 for control, untreated, and CTX + placebo, and N=2 for CTX + vaccine). (B) Unpurified effector cells from mice were incubated at a 10:1 ratio (N=1, all groups). CTX= cyclophosphamide; LET= letrozole
Supplementary Figure Legend from A Let-7 MicroRNA SNP in the KRAS 3′UTR Is Prognostic in Early-Stage Colorectal Cancer
Authors: Smits Kim M. , Paranjape Trupti , Nallur Sunitha , Wouters Kim A.D. , Weijenberg Matty P. , Schouten Leo J. , van den Brandt Piet A. , Bosman Fred T. , Weidhaas Joanne B. , van Engeland Manon
Published: April 2023

PDF file - 32KB
Supplementary Figure 1 from A Let-7 MicroRNA SNP in the KRAS 3′UTR Is Prognostic in Early-Stage Colorectal Cancer
Authors: Smits Kim M. , Paranjape Trupti , Nallur Sunitha , Wouters Kim A.D. , Weijenberg Matty P. , Schouten Leo J. , van den Brandt Piet A. , Bosman Fred T. , Weidhaas Joanne B. , van Engeland Manon
Published: April 2023

PDF file - 35KB
Supplementary Figure 1 from L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
Authors: Mehta Neelima R. , Wurz Gregory T. , Burich Rebekah A. , Greenberg Brittany E. , Griffey Stephen , Gutierrez Audrey , Bell Katie E. , McCall Jamie L. , Wolf Michael , DeGregorio Michael
Published: April 2023

PDF file - 87K, Representative MMT tumors stained with H&E (A), ER-alpha IHC (B), and hMUC1 (C) (bar = 100 mu m)
Supplementary Table 2 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
Authors: Schwartzberg Lee S. , Tauer Kurt W. , Hermann Robert C. , Makari-Judson Grace , Isaacs Claudine , Beck J. Thaddeus , Kaklamani Virginia , Stepanski Edward J. , Rugo Hope S. , Wang Wei , Bell-McGuinn Katherine , Kirshner Jeffrey J. , Eisenberg Peter , Emanuelson Richard , Keaton Mark , Levine Ellis , Medgyesy Diana C. , Qamar Rubina , Starr Alexander , Ro Sunhee Kwon , Lokker Nathalie A. , Hudis Clifford A.
Published: April 2023

PDF file - 46K, Overall Survival in Prespecified Subgroups
Supplementary Figure 2 from LINE-1 Hypomethylation, DNA Copy Number Alterations, and CDK6 Amplification in Esophageal Squamous Cell Carcinoma
Authors: Baba Yoshifumi , Watanabe Masayuki , Murata Asuka , Shigaki Hironobu , Miyake Keisuke , Ishimoto Takatsugu , Iwatsuki Masaaki , Iwagami Shiro , Yoshida Naoya , Oki Eiji , Sakamaki Kentaro , Nakao Mitsuyoshi , Baba Hideo
Published: April 2023

PDF file - 188K, Cyclin D1 expression, LINE-1 methylation level, and patient prognosis in esophageal cancer.
Supplementary Figure 1 from Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer
Authors: Sewell Andrew , Brown Brandee , Biktasova Asel , Mills Gordon B. , Lu Yiling , Tyson Darren R. , Issaeva Natalia , Yarbrough Wendell G.
Published: April 2023

PDF file - 124KB, Kaplan-Meier curves showing overall survival of patients with wild type and mutant PIK3CA tumors within HPV(+) group.
Supplementary Methods and Figure Legends and Figures from The G-Protein–Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis
Authors: Nikitenko Leonid L. , Leek Russell , Henderson Stephen , Pillay Nischalan , Turley Helen , Generali Daniele , Gunningham Sarah , Morrin Helen R. , Pellagatti Andrea , Rees Margaret C.P. , Harris Adrian L. , Fox Stephen B.
Published: April 2023

PDF file, 840K, Supplementary Materials and Methods, Supplementary Figure Legends and Supplementary Figures Supplementary Figure S1. Transcriptional profile of ADM expression in paired patient-matched normal and carcinoma tissues. Supplementary Figure S2. CLR expression in tumor cells and tumor vessels in renal carcinoma. Supplementary Figure S3. High CLR expression in tumor cells and tumor vessels in renal cancers compared to normal tissues and its association with histology Supplementary Figure S4. Terminal glycosylation of CLR expressed in renal tumor tissues and cell lines. Supplementary Figure S5. Expression of ADM and RAMPs 1, 2 and 3 mRNAs in cell lines and renal tissues was analyzed by reverse transcriptase PCR (RT-PCR). Supplementary Figure S6. High CLR expression in tumor cells and tumor vessels in renal tumors compared to normal tissues and its association with T stage.
Supplemental Figure 1 from Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
Authors: Kadoch Cigall , Li Jing , Wong Valerie S. , Chen Lingjing , Cha Soonmee , Munster Pamela , Lowell Clifford A. , Shuman Marc A. , Rubenstein James L.
Published: April 2023

Supplemental Figure 1. Elevated C3a des-arg concentration in CSF is associated with shorter progression-free survival in newly-diagnosed patients with CNS involvement of aggressive non-Hodgkinâ€™s lymphoma (N=35). The survival for the seven patients with elevated C3a in CSF at diagnosis was significantly shorter than for the 28 patients with low CSF C3a concentration at diagnosis. (P<0.019). In this cohort, both age >60 and ECOG >1 were also associated with shorter progression-free survival (P<0.05).
Supplementary Figure 3 from SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Authors: Leibowitz Michael S. , Srivastava Raghvendra M. , Andrade Filho Pedro A. , Egloff Ann Marie , Wang Lin , Seethala Raja R. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 66K, SHP1 depletion upregulates neither pSTAT1 nor APM components
Supplementary Figure 1 from SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Authors: Leibowitz Michael S. , Srivastava Raghvendra M. , Andrade Filho Pedro A. , Egloff Ann Marie , Wang Lin , Seethala Raja R. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 152K, SHP1 is not overexpressed in HNC tissue in comparison to normal mucosa
Supplementary Table S3 from The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis
Authors: Luscan Armelle , Shackleford Ghjuvan'Ghjacumu , Masliah-Planchon Julien , Laurendeau Ingrid , Ortonne Nicolas , Varin Jennifer , Lallemand François , Leroy Karen , Dumaine Valérie , Hivelin Mikael , Borderie Didier , De Raedt Thomas , Valeyrie-Allanore Laurence , Larousserie Frédérique , Terris Benoît , Lantieri Laurent , Vidaud Michel , Vidaud Dominique , Wolkenstein Pierre , Parfait Béatrice , Bièche Ivan , Massaad Charbel , Pasmant Eric
Published: April 2023

PDF file 104K, mRNA levels of 89 Wnt pathway genes in seven dermal neurofibromas, seven plexiform neurofibromas, and eight MPNSTs
Supplementary Figure 1 from In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Authors: Schalper Kurt A. , Velcheti Vamsidhar , Carvajal Daniel , Wimberly Hallie , Brown Jason , Pusztai Lajos , Rimm David L.
Published: April 2023

PDF file - 9837K, Figure S1. Validation of in situ PD-L1 mRNA detection using quantitative fluorescence in cell lines and human tissues.
Figure S1 from HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma
Authors: Cariani Elisabetta , Pilli Massimo , Zerbini Alessandro , Rota Cristina , Olivani Andrea , Zanelli Paola , Zanetti Adele , Trenti Tommaso , Ferrari Carlo , Missale Gabriele
Published: April 2023

Figure S1 - PDF file 38K, KIR genotype distribution in 61 patients with HCC. SR: Surgical Resection; RTA: Radiofrequency Thermal Ablation
Supplementary Figure 7 from Downregulation of miR-138 Sustains NF-κB Activation and Promotes Lipid Raft Formation in Esophageal Squamous Cell Carcinoma
Authors: Gong Hui , Song Libing , Lin Chuyong , Liu Aibin , Lin Xi , Wu Jueheng , Li Mengfeng , Li Jun
Published: April 2023

PDF file - 21 KB, miR-138 directly suppresses multiple lipid rafts components.
Supplementary Table from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Authors: Ye Qunrui , Song De-Gang , Poussin Mathilde , Yamamoto Tori , Best Andrew , Li Chunsheng , Coukos George , Powell Daniel J.
Published: April 2023

Supplementary Table - PDF file 64K, Table 1. Relative expression of CD137 and PD-1 on tumor-activated TILs
CCR Translation for This Article from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Authors: Ye Qunrui , Song De-Gang , Poussin Mathilde , Yamamoto Tori , Best Andrew , Li Chunsheng , Coukos George , Powell Daniel J.
Published: April 2023

CCR Translation for This Article from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Supplementary Figures 1 - 5 from Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
Authors: Shi Xianping , Chen Xin , Li Xiaofen , Lan Xiaoying , Zhao Chong , Liu Shouting , Huang Hongbiao , Liu Ningning , Liao Siyan , Song Wenbin , Zhou Ping , Wang Shunqing , Xu Li , Wang Xuejun , Dou Q. Ping , Liu Jinbao
Published: April 2023

Supplementary figure 1. Molecular weight of proteins. All the molecular weight of proteins detected in this current study were labeled. M.W: molecular weight. Supplementary Fig. 2. KBM5 and KBM5-T315I cells were exposed to IM in various concentrations for 48 hours, and then were subjected to MTS assay. Supplementary Fig. 3. GA does not affect mRNA expression of Bcr-Abl. KBM5 and KBM5-T315I cells were exposed to 0.5 μM GA for 3 or 6 hours. The Bcr-Abl mRNA expression was measured by RT-qPCR and its expression level relative to the control was calculated. Mean{plus minus}SD (n=3). Supplementary Fig. 4. KBM5 and KBM5-T315I cells were treated with GA (0.5 μM) with/without IM (200 nM) for 12 hours. PARP, total and phosphorylated Bcr-Abl were detected by Western blot. Supplementary Fig. 5. Synergistic effect of the combination of GA and IM in KBM5 and KBM5-T315I cells was assessed by MTS assay for 48 h. CI is plotted against the fraction affected. A reference line is drawn at CI=1. Combination index values < 1.0 correspond to a synergistic interaction.
Supplementary Figure 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Authors: Coiffier Bertrand , Li Weimin , Henitz Erin D. , Karkera Jayaprakash D. , Favis Reyna , Gaffney Dana , Shapiro Alice , Theocharous Panteli , Elsayed Yusri A. , van de Velde Helgi , Schaffer Michael E. , Osmanov Evgenii A. , Hong Xiaonan , Scheliga Adriana , Mayer Jiri , Offner Fritz , Rule Simon , Teixeira Adriana , Romejko-Jarosinska Joanna , de Vos Sven , Crump Michael , Shpilberg Ofer , Zinzani Pier Luigi , Cakana Andrew , Esseltine Dixie-Lee , Mulligan George , Ricci Deborah
Published: April 2023

Supplementary Figure 2 PDF file 135K, Forest plot for single marker (A) protein and (B) germ-line DNA biomarker analyses
Supplementary Figure 1 from Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Authors: Kohno Mikihiro , Okamoto Tatsuro , Suda Kenichi , Shimokawa Mototsugu , Kitahara Hirokazu , Shimamatsu Shinichiro , Konishi Hideyuki , Yoshida Tsukihisa , Takenoyama Mitsuhiro , Yano Tokujiro , Maehara Yoshihiko
Published: April 2023

PDF file - 158KB, Supplementary figure S1. Kaplan-Meier postoperative RFS and OS curves by aromatase expression level. N: number of patients in each category.
Supplementary Table 3 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
Authors: Bartlett Edmund K. , Fetsch Patricia A. , Filie Armando C. , Abati Andrea , Steinberg Seth M. , Wunderlich John R. , White Donald E. , Stephens Daniel J. , Marincola Francesco M. , Rosenberg Steven A. , Kammula Udai S.
Published: April 2023

PDF file - 50K, Dendrogram distance matrix for all melanoma differentiation antigens. Dendrogram distant matrix calculated from DendroUPGMA.
Supplementary Fig. 3 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Authors: Phillips Gail D. Lewis , Fields Carter T. , Li Guangmin , Dowbenko Donald , Schaefer Gabriele , Miller Kathy , Andre Fabrice , Burris Howard A. , Albain Kathy S. , Harbeck Nadia , Dieras Veronique , Crivellari Diana , Fang Liang , Guardino Ellie , Olsen Steven R. , Crocker Lisa M. , Sliwkowski Mark X.
Published: April 2023

PDF file 64K, NRG protects ZR-75-30, but not HCC1954, breast cancer cells from T-DM1 induced apoptosis
Supplementary Fig. 2 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Authors: Phillips Gail D. Lewis , Fields Carter T. , Li Guangmin , Dowbenko Donald , Schaefer Gabriele , Miller Kathy , Andre Fabrice , Burris Howard A. , Albain Kathy S. , Harbeck Nadia , Dieras Veronique , Crivellari Diana , Fang Liang , Guardino Ellie , Olsen Steven R. , Crocker Lisa M. , Sliwkowski Mark X.
Published: April 2023

PDF file 12K, Kaplan-Meier plot of time-to-tumor doubling in the MDA-175 breast cancer xenograft model after treatment with T-DM1 and pertuzumab
Supplementary Fig. 1 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Authors: Phillips Gail D. Lewis , Fields Carter T. , Li Guangmin , Dowbenko Donald , Schaefer Gabriele , Miller Kathy , Andre Fabrice , Burris Howard A. , Albain Kathy S. , Harbeck Nadia , Dieras Veronique , Crivellari Diana , Fang Liang , Guardino Ellie , Olsen Steven R. , Crocker Lisa M. , Sliwkowski Mark X.
Published: April 2023

Supplementary Fig. 1 PDF file 71K, Combination Index vs. fractional effect plots showing synergy with T-DM1 combined with pertuzumab in MDA-175, Calu-3, and BT-474 cells
Supplementary Figure Legends from Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers
Authors: Di Caro Giuseppe , Bergomas Francesca , Grizzi Fabio , Doni Andrea , Bianchi Paolo , Malesci Alberto , Laghi Luigi , Allavena Paola , Mantovani Alberto , Marchesi Federica
Published: April 2023

PDF file - 89K
Supplementary Figure 1 from Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers
Authors: Di Caro Giuseppe , Bergomas Francesca , Grizzi Fabio , Doni Andrea , Bianchi Paolo , Malesci Alberto , Laghi Luigi , Allavena Paola , Mantovani Alberto , Marchesi Federica
Published: April 2023

PDF file - 124K, Kaplan-Meier curves showing prognostic relevance of MS status according to the density of TLT.
Supplementary Fig S1 from Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer
Authors: Yi Joo Mi , Guzzetta Angela A. , Bailey Vasudev J. , Downing Stephanie R. , Van Neste Leander , Chiappinelli Katherine B. , Keeley Brian P. , Stark Alejandro , Herrera Alexander , Wolfgang Christopher , Pappou Emmanouil P. , Iacobuzio-Donahue Christine A. , Goggins Michael G. , Herman James G. , Wang Tza-Huei , Baylin Stephen B. , Ahuja Nita
Published: April 2023

- PDF file 69K, Supplementary Fig. S1. Schematic representation of the study design used in this project
Supplemental Methods from Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice
Authors: van de Steeg Evita , van Esch Anita , Wagenaar Els , Kenworthy Kathryn E. , Schinkel Alfred H.
Published: April 2023

PDF file - 86K,Descriptive RT-PCR data about the expression of other transporter proteins in livers of knockout and humanized transgenic OATP mice
Supplemental Figure Legends from Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice
Authors: van de Steeg Evita , van Esch Anita , Wagenaar Els , Kenworthy Kathryn E. , Schinkel Alfred H.
Published: April 2023

PDF file - 76K,Supplementary Figure legends
Supplementary Materials and Methods from Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer
Authors: Le Magnen Clémentine , Bubendorf Lukas , Rentsch Cyrill A. , Mengus Chantal , Gsponer Joel , Zellweger Tobias , Rieken Malte , Thalmann George N. , Cecchini Marco G. , Germann Markus , Bachmann Alexander , Wyler Stephen , Heberer Michael , Spagnoli Giulio C.
Published: April 2023

PDF file, 41K.
Supplementery Figure S2 from GKN1–miR-185–DNMT1 Axis Suppresses Gastric Carcinogenesis through Regulation of Epigenetic Alteration and Cell Cycle
Authors: Yoon Jung Hwan , Choi Yoo Jin , Choi Won Suk , Ashktorab Hassan , Smoot Duane T. , Nam Suk Woo , Lee Jung Young , Park Won Sang
Published: April 2023

Supplementery Figure S2 - PDF file 687K, Epigenetic regulation of CDKN2A in AGS gastric cancer cell lines
Supplementary Figure S8 from GKN1–miR-185–DNMT1 Axis Suppresses Gastric Carcinogenesis through Regulation of Epigenetic Alteration and Cell Cycle
Authors: Yoon Jung Hwan , Choi Yoo Jin , Choi Won Suk , Ashktorab Hassan , Smoot Duane T. , Nam Suk Woo , Lee Jung Young , Park Won Sang
Published: April 2023

Supplementary Figure S8 - PDF file 188K, Sequencing results of E-cadherin and CDKN2A promoter regions
Supplementary Table S3 from Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer
Authors: Janssens Geert O. , Rademakers Saskia E. , Terhaard Chris H. , Doornaert Patricia A. , Bijl Hendrik P. , van den Ende Piet , Chin Alim , Takes Robert P. , de Bree Remco , Hoogsteen Ilse J. , Bussink Johan , Span Paul N. , Kaanders Johannes H.
Published: April 2023

Table S3. Treatment delivery for all patients (N=345) and the patients presenting with anemia (N=54).
Supplementary Table S1 from Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer
Authors: Janssens Geert O. , Rademakers Saskia E. , Terhaard Chris H. , Doornaert Patricia A. , Bijl Hendrik P. , van den Ende Piet , Chin Alim , Takes Robert P. , de Bree Remco , Hoogsteen Ilse J. , Bussink Johan , Span Paul N. , Kaanders Johannes H.
Published: April 2023

Table S1. Participating institutions for all patients (N=345) and patients presenting with anemia(N=54).
Supplementary Legend from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Authors: Gucalp Ayca , Tolaney Sara , Isakoff Steven J. , Ingle James N. , Liu Minetta C. , Carey Lisa A. , Blackwell Kimberly , Rugo Hope , Nabell Lisle , Forero Andres , Stearns Vered , Doane Ashley S. , Danso Michael , Moynahan Mary Ellen , Momen Lamia F. , Gonzalez Joseph M. , Akhtar Arooj , Giri Dilip D. , Patil Sujata , Feigin Kimberly N. , Hudis Clifford A. , Traina Tiffany A.
Published: April 2023

Supplementary Legend - PDF file 22K, Supplementary Legend
Supplementary Figure 2 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Authors: Gucalp Ayca , Tolaney Sara , Isakoff Steven J. , Ingle James N. , Liu Minetta C. , Carey Lisa A. , Blackwell Kimberly , Rugo Hope , Nabell Lisle , Forero Andres , Stearns Vered , Doane Ashley S. , Danso Michael , Moynahan Mary Ellen , Momen Lamia F. , Gonzalez Joseph M. , Akhtar Arooj , Giri Dilip D. , Patil Sujata , Feigin Kimberly N. , Hudis Clifford A. , Traina Tiffany A.
Published: April 2023

Supplementary Figure 2 - PDF file 275K, Supplementary Figure 2A-D. Changes in hormone levels over time per patient; responders (stable disease >6 months) highlighted in red
Supplementary Table 1 from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Authors: Saif Muhammad Wasif , Takimoto Chris , Mita Monica , Banerji Udai , Lamanna Nicole , Castro Januario , O'Brien Susan , Stogard Christopher , Von Hoff Daniel
Published: April 2023

PDF file 76K, Demographic characteristics of Patients
Supplementary Figures 1-3 from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Authors: Saif Muhammad Wasif , Takimoto Chris , Mita Monica , Banerji Udai , Lamanna Nicole , Castro Januario , O'Brien Susan , Stogard Christopher , Von Hoff Daniel
Published: April 2023

PDF files 200K, Supplemental Figure 1: BIIB021 Activity in Solid Tumor; Supplemental Figure 2: Changes in FDG-PET Imaging; Supplemental Figure 3: Clinical Activity Observed with BIIB021 in CLL
Supplementary Table 2 from Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer
Authors: Wojtalla Anna , Fischer Barbara , Kotelevets Nataliya , Mauri Francesco A. , Sobek Jens , Rehrauer Hubert , Wotzkow Carlos , Tschan Mario P. , Seckl Michael J. , Zangemeister-Wittke Uwe , Arcaro Alexandre
Published: April 2023

PDF file - 97K, Genetic alterations and expression profile of the PI3K p110α and the tumor suppressors PTEN, TP53, and RB in 3 SCLC cell lines
Supplementary Table 1 from Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer
Authors: Wojtalla Anna , Fischer Barbara , Kotelevets Nataliya , Mauri Francesco A. , Sobek Jens , Rehrauer Hubert , Wotzkow Carlos , Tschan Mario P. , Seckl Michael J. , Zangemeister-Wittke Uwe , Arcaro Alexandre
Published: April 2023

PDF file - 83K, Biostatistical analysis of the transcriptional networks impaired by p110α inhibition
Supplementary Materials and Methods from Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Authors: Li Bin , Tsao Sai Wah , Chan Kwok Wah , Ludwig Dale L. , Novosyadlyy Ruslan , Li Yuk Yin , He Qing Yu , Cheung Annie L.M.
Published: April 2023

PDF file - 74KB
Supplementary Table 2 from Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer
Authors: Wick Darin A. , Webb John R. , Nielsen Julie S. , Martin Spencer D. , Kroeger David R. , Milne Katy , Castellarin Mauro , Twumasi-Boateng Kwame , Watson Peter H. , Holt Rob A. , Nelson Brad H.
Published: April 2023

PDF file - 69K, Tested minimal peptides and corresponding MHC binding scores for Patient 2.
Supplementary Table 7 from Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors
Authors: Chiechi Antonella , Novello Chiara , Magagnoli Giovanna , Petricoin Emanuel F. , Deng Jianghong , Benassi Maria S. , Picci Piero , Vaisman Iosif , Espina Virginia , Liotta Lance A.
Published: April 2023

PDF file - 58K, Machine learning dataset characteristics.
Supplementary Table 2 from Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors
Authors: Chiechi Antonella , Novello Chiara , Magagnoli Giovanna , Petricoin Emanuel F. , Deng Jianghong , Benassi Maria S. , Picci Piero , Vaisman Iosif , Espina Virginia , Liotta Lance A.
Published: April 2023

XLSX file - 33K, List of primary antibodies used to probe RPMA slides.
Supplementary Table 1 from Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors
Authors: Chiechi Antonella , Novello Chiara , Magagnoli Giovanna , Petricoin Emanuel F. , Deng Jianghong , Benassi Maria S. , Picci Piero , Vaisman Iosif , Espina Virginia , Liotta Lance A.
Published: April 2023

XLSX file - 60K, Bone metastasis specimen study set.
Supplementary Figure 2 from PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma
Authors: Shigaki Hironobu , Baba Yoshifumi , Watanabe Masayuki , Murata Asuka , Ishimoto Takatsugu , Iwatsuki Masaaki , Iwagami Shiro , Nosho Katsuhiko , Baba Hideo
Published: April 2023

PDF File - 95K, K-M curves according to mutation sites.
Supplementary Table 1 from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 133K, Clinicopathological features of the colorectal cancer patient cohort.
Supplementary Figure 8 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 76KB, GM-CSF facilitates CTC clearance by boosting host immunity.
Supplementary Figure 5 from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 223K, Effect of 5-FU treatment on migration and proliferation of CRC cell lines.
Supplementary Figure 4 from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 179K, Effect of AXL siRNA on migration, proliferation and survival of CRC cells.
Supplementary Figure 3 from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 190K, Effect of AXL small molecule inhibition on downstream signalling pathways and migration in CRC cell lines.
Supplementary Figure 4 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 177KB, The serum profiles of various cytokines in mice with or without metastasis.
Supplementary Figure 2 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 248KB, The number of CTCs detected from forearm vein of clinical stage I/II lung cancer patients are higher than those of stages III and IV.
Supplementary Figure 10 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 846KB, Expression of IL-17A was higher CRC with recurrence.
Supplementary Figure 1 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 590KB, CTCs are more abundant in blood from the mesenteric vein than in blood from the forearm vein.
Supplementary Methods from Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
Authors: Dekervel Jeroen , Hompes Daphne , van Malenstein Hannah , Popovic Dusan , Sagaert Xavier , De Moor Bart , Van Cutsem Eric , D'Hoore André , Verslype Chris , van Pelt Jos
Published: April 2023

PDF file - 98KB
Supplementary Figure 3 from Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
Authors: Dekervel Jeroen , Hompes Daphne , van Malenstein Hannah , Popovic Dusan , Sagaert Xavier , De Moor Bart , Van Cutsem Eric , D'Hoore André , Verslype Chris , van Pelt Jos
Published: April 2023

PDF file - 321KB, The p53 KEGG pathway is highly altered under chronic hypoxic conditions.
Supplementary Figure 2 from Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
Authors: Dekervel Jeroen , Hompes Daphne , van Malenstein Hannah , Popovic Dusan , Sagaert Xavier , De Moor Bart , Van Cutsem Eric , D'Hoore André , Verslype Chris , van Pelt Jos
Published: April 2023

PDF file - 85KB, ROC curves of the Leuven cohort and the external AMC-AJCCII-90 data set.
Supplementary Table 2 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

XLSX file - 165K, Response of Panc502 to 125 anti-neoplastic drugs.
Supplementary Table 1 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

XLSX file - 125K, Drugs with 40-100% inhibition.
Supplementary Figure 3 from Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
Authors: Chen Chun-Han , Chen Mei-Chuan , Wang Jing-Chi , Tsai An-Chi , Chen Ching-Shih , Liou Jing-Ping , Pan Shiow-Lin , Teng Che-Ming
Published: April 2023

PDF file - 1305KB, Antitumor activity of MPT0E028 plus sorafenib in a Hep3B xenograft model.
Supplementary Figure 8 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 1893K, FM108 ovarian cell line production.
Supplementary Figure 2 from Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
Authors: Chen Chun-Han , Chen Mei-Chuan , Wang Jing-Chi , Tsai An-Chi , Chen Ching-Shih , Liou Jing-Ping , Pan Shiow-Lin , Teng Che-Ming
Published: April 2023

PDF file - 1939KB, Effects of sorafenib in combination with MPT0E028 on cell proliferation, viability and LDH activity in liver cancer cell lines.
Supplementary Figure 2 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 87K, Breeding strategy for production and maintenance of the SCID hprt-null mouse.
Supplementary Table 1 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
Authors: Proia David A. , Zhang Chaohua , Sequeira Manuel , Jimenez John-Paul , He Suqin , Spector Neil , Shapiro Geoffrey I. , Tolaney Sara , Nagai Masazumi , Acquaviva Jaime , Smith Donald L. , Sang Jim , Bates Richard C. , El-Hariry Iman
Published: April 2023

PDF file - 63K, In vitro cytoxicity values of ganetespib in TNBC cell lines.
Supporting Table 1 from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential
Authors: Qiu Yunping , Cai Guoxiang , Zhou Bingsen , Li Dan , Zhao Aihua , Xie Guoxiang , Li Houkai , Cai Sanjun , Xie Dong , Huang Changzhi , Ge Weiting , Zhou Zhanxiang , Xu Lisa X. , Jia Weiping , Zheng Shu , Yen Yun , Jia Wei
Published: April 2023

PDF file 63K, VIP values from OPLS-DA models and p values in the samples the Hangzhou, Beijing and City of Hope cohorts
Supplementary Figure 2 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
Authors: Proia David A. , Zhang Chaohua , Sequeira Manuel , Jimenez John-Paul , He Suqin , Spector Neil , Shapiro Geoffrey I. , Tolaney Sara , Nagai Masazumi , Acquaviva Jaime , Smith Donald L. , Sang Jim , Bates Richard C. , El-Hariry Iman
Published: April 2023

PDF file - 2670K, Ganetespib treatment reduces lung metastatic burden in an experimental metastasis model and has minimal effects on primary tumor growth in an orthotopic model.
Supplementary Figure 1 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
Authors: Proia David A. , Zhang Chaohua , Sequeira Manuel , Jimenez John-Paul , He Suqin , Spector Neil , Shapiro Geoffrey I. , Tolaney Sara , Nagai Masazumi , Acquaviva Jaime , Smith Donald L. , Sang Jim , Bates Richard C. , El-Hariry Iman
Published: April 2023

PDF file - 3929K, Effect of ganetespib on the migratory capacity of MDA-MB-231 cells.
Supplementary Legends from PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Authors: Walsh Katherine , McKinney Matthew S. , Love Cassandra , Liu Qingquan , Fan Alice , Patel Amee , Smith Jason , Beaven Anne , Jima Dereje D. , Dave Sandeep S.
Published: April 2023

PDF file - 38 KB, The Supplementary Data Legend provides the legends for Supplementary Table S1 and Supplementary Figure S1.
Related Article from The Role of Protein Kinase CK2 in Glioblastoma Development
Authors: Ji Haitao , Lu Zhimin
Published: April 2023

Related Article from The Role of Protein Kinase CK2 in Glioblastoma Development
Supplementary Table S1 from Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Authors: Pinker Katja , Bogner Wolfgang , Baltzer Pascal , Karanikas Georgios , Magometschnigg Heinrich , Brader Peter , Gruber Stephan , Bickel Hubert , Dubsky Peter , Bago-Horvath Zsuzsanna , Bartsch Rupert , Weber Michael , Trattnig Siegfried , Helbich Thomas H.
Published: April 2023

Detailed results of dynamic contrast-enhanced MR imaging of the breast, DWI, 3D 1H-MRSI and 18FDG PET the assigned final MRI BI-RADSÂ® classification for benign and malignant lesions.
Supplementary Figure 3 from A Novel Aldehyde Dehydrogenase-3 Activator (Alda-89) Protects Submandibular Gland Function from Irradiation without Accelerating Tumor Growth
Authors: Xiao Nan , Cao Hongbin , Chen Che-Hong , Kong Christina S. , Ali Rehan , Chan Cato , Sirjani Davud , Graves Edward , Koong Albert , Giaccia Amato , Mochly-Rosen Daria , Le Quynh-Thu
Published: April 2023

PDF file, 145K, Alda-89 does not promote cell proliferation in different HNC cell lines.
Supplementary Figure 2 from A Novel Aldehyde Dehydrogenase-3 Activator (Alda-89) Protects Submandibular Gland Function from Irradiation without Accelerating Tumor Growth
Authors: Xiao Nan , Cao Hongbin , Chen Che-Hong , Kong Christina S. , Ali Rehan , Chan Cato , Sirjani Davud , Graves Edward , Koong Albert , Giaccia Amato , Mochly-Rosen Daria , Le Quynh-Thu
Published: April 2023

PDF file, 90K, Protein expression of ALDH3A1 & 2 in different HNC cell lines.
Supplementary Figure 5 from Regulation of Cell Proliferation and Migration by Keratin19-Induced Nuclear Import of Early Growth Response-1 in Breast Cancer Cells
Authors: Ju Ji-hyun , Yang Wonseok , Lee Kyung-min , Oh Sunhwa , Nam KeeSoo , Shim Sarah , Shin Soon Young , Gye Myung Chan , Chu In-Sun , Shin Incheol
Published: April 2023

Supplementary Figure 5 - PDF file 2097K, KRT19 regulated nuclear localization of Egr1 transcriptional factor
Supplementary Figures from Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
Authors: Warren Robert S. , Atreya Chloe E. , Niedzwiecki Donna , Weinberg Vivian K. , Donner David B. , Mayer Robert J. , Goldberg Richard M. , Compton Carolyn C. , Zuraek Marlene B. , Ye Cynthia , Saltz Leonard B. , Bertagnolli Monica M.
Published: April 2023

Supplementary Figures - PDF file 341K, Figure S1. CALGB 89803 Consolidated Standards of Reporting Trials (CONSORT) diagram. Cancer and Leukemia Group B (CALGB) 89803 conducted a randomized trial of adjuvant therapy in patients with stage III colorectal cancers. The trial included prospective determination of the relationship between tumor TP53 mutational status, gender, and treatment outcome as a secondary study end point. CPT-11, irinotecan; FU, fluorouracil; LV, leucovorin. Figure S2. Kaplan-Meier estimates of disease-free survival related to TP53 status for men and women in CALGB 89803. A. DFS in the presence or absence of any TP53 mutation showed no differences among women (P = 0.16). B. Similarly, DFS in the presence or absence of any TP53 mutation showed no differences among men (P = 0.16). WT = wild type TP53; Mutant = any TP53 mutation in exons 5-8). Corresponding 5 year survival estimates are in Table 2, Rows 5 and 6. Figure S3. Kaplan-Meier estimates of disease-free survival related to TP53 status among men in CALGB 89803. Men whose tumors harbored wild-type (WT) TP53, or tumors with mutations in the zinc-binding (ZB) or non-zinc binding (NZB) domains of TP53 were treated with 5FU/LV (Figure S3A) or IFL (Figure S3B). No differences in survival according to TP53 genotype were observed among men treated with 5FU/LV (P = 0.65) or IFL, P = 0.14. Corresponding 5 year survival estimates are in Table 2, Rows 16-17. Figure S4. Kaplan-Meier estimates of disease-free survival related to TP53 status among women in CALGB 89803. Women whose tumors harbored wild-type TP53, or tumors with mutations in the zinc-binding (ZB) or non-zinc binding (NZB) domains of TP53 were treated with 5FU/LV or IFL. (A) Women with TP53 WT tumors experienced a statistically similar outcome on either treatment arm (P = 0.35. (B) Women whose tumors harbored ZB mutations may have benefited marginally from IFL as compared to 5FU/LV (P = 0.10). (C) Women whose tumors harbored NZB mutations experienced a trend toward better survival with 5FU/LV compared to IFL (P = 0.08)
Supplementary Fig. 1 from Regulation of Cell Proliferation and Migration by Keratin19-Induced Nuclear Import of Early Growth Response-1 in Breast Cancer Cells
Authors: Ju Ji-hyun , Yang Wonseok , Lee Kyung-min , Oh Sunhwa , Nam KeeSoo , Shim Sarah , Shin Soon Young , Gye Myung Chan , Chu In-Sun , Shin Incheol
Published: April 2023

Supplementary Fig. 1 - PDF file 185K, Inhibition of KRT19 up-regulates cell proliferation
Supplementary Figure 1 from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Authors: Amiri-Kordestani Laleh , Luchenko Victoria , Peer Cody J. , Ghafourian Kambiz , Reynolds James , Draper Deb , Frye Robin , Woo Sue , Venzon David , Wright John , Skarulis Monica , Figg William D. , Fojo Tito , Bates Susan E. , Piekarz Richard L.
Published: April 2023

Supplementary Figure 1 - PDF file 176K, Supplementary Figure 1: Comparison of dose-normalized CMAX (A) and AUCLAST (B) for the present phase I trial versus data obtained on the phase II NCI1312 trial
Supplementary Figure 2 from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Authors: Agarwal Anupriya , MacKenzie Ryan J. , Pippa Raffaella , Eide Christopher A. , Oddo Jessica , Tyner Jeffrey W. , Sears Rosalie , Vitek Michael P. , Odero María D. , Christensen Dale J. , Druker Brian J.
Published: April 2023

PDF file - 212KB, SET is overexpressed in primary AML cells and OP449 inhibits growth of primary AML patient cells.
Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Authors: Gini Beatrice , Zanca Ciro , Guo Deliang , Matsutani Tomoo , Masui Kenta , Ikegami Shiro , Yang Huijun , Nathanson David , Villa Genaro R. , Shackelford David , Zhu Shaojun , Tanaka Kazuhiro , Babic Ivan , Akhavan David , Lin Kelly , Assuncao Alvaro , Gu Yuchao , Bonetti Bruno , Mortensen Deborah S. , Xu Shuichan , Raymon Heather K. , Cavenee Webster K. , Furnari Frank B. , James C. David , Kroemer Guido , Heath James R. , Hege Kristen , Chopra Rajesh , Cloughesy Timothy F. , Mischel Paul S.
Published: April 2023

PDF file - 5321K, In vitro and in vivo pharmacological inhibition of autophagy sensitizes U87EGFRvIII cells and orthotopic xenografts to CC214-1/CC214-2 mediated apoptosis.
Supplementary Figure 5 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
Authors: Ria Roberto , Catacchio Ivana , Berardi Simona , De Luisi Annunziata , Caivano Antonella , Piccoli Claudia , Ruggieri Vitalba , Frassanito Maria Antonia , Ribatti Domenico , Nico Beatrice , Annese Tiziana , Ruggieri Simona , Guarini Attilio , Minoia Carla , Ditonno Paolo , Angelucci Emanuele , Derudas Daniele , Moschetta Michele , Dammacco Franco , Vacca Angelo
Published: April 2023

PDF file - 166K, HIF-1alpha protein does not correlate with AKT, and VHL.
Supplementary Table 2 from A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
Authors: Venugopal Balaji , Baird Richard , Kristeleit Rebecca S. , Plummer Ruth , Cowan Richard , Stewart Adam , Fourneau Nele , Hellemans Peter , Elsayed Yusri , Mcclue Steve , Smit Johan W. , Forslund Ann , Phelps Charles , Camm John , Evans T.R. Jeffry , de Bono Johann S. , Banerji Udai
Published: April 2023

Supplementary Table 2 - PDF file 58K, A summary of PK parameters of quisinostat estimated on day 1